DK4058060T3 - Type i-interferon-hæmning ved systemisk lupus erythematosus - Google Patents

Type i-interferon-hæmning ved systemisk lupus erythematosus Download PDF

Info

Publication number
DK4058060T3
DK4058060T3 DK20804531.0T DK20804531T DK4058060T3 DK 4058060 T3 DK4058060 T3 DK 4058060T3 DK 20804531 T DK20804531 T DK 20804531T DK 4058060 T3 DK4058060 T3 DK 4058060T3
Authority
DK
Denmark
Prior art keywords
type
lupus erythematosus
systemic lupus
interferon inhibition
interferon
Prior art date
Application number
DK20804531.0T
Other languages
English (en)
Inventor
Anna Berglind
Gabriel Abreu
Lilia Pineda
Raj Tummala
Anca Askanase
Christophe Richez
Eric Morand
Ian Bruce
Philip Brohawn
Richard Furie
Sang-Cheol Bae
Yoshiya Tanaka
Victoria Werth
Ronald Van Vollenhoven
David Isenberg
Ed Vital
Michelle Kahlenberg
Rubana Kalyani
Kenneth Kalunian
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of DK4058060T3 publication Critical patent/DK4058060T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
DK20804531.0T 2019-11-11 2020-11-11 Type i-interferon-hæmning ved systemisk lupus erythematosus DK4058060T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962933672P 2019-11-11 2019-11-11
US202063031848P 2020-05-29 2020-05-29
US202063089345P 2020-10-08 2020-10-08
PCT/EP2020/081770 WO2021094378A1 (en) 2019-11-11 2020-11-11 Type i interferon inhibition in systemic lupus erythematosus

Publications (1)

Publication Number Publication Date
DK4058060T3 true DK4058060T3 (da) 2025-03-17

Family

ID=73344065

Family Applications (1)

Application Number Title Priority Date Filing Date
DK20804531.0T DK4058060T3 (da) 2019-11-11 2020-11-11 Type i-interferon-hæmning ved systemisk lupus erythematosus

Country Status (16)

Country Link
US (1) US20220396630A1 (da)
EP (2) EP4494712A3 (da)
JP (1) JP2023501462A (da)
KR (1) KR102766960B1 (da)
CN (1) CN114728059A (da)
AU (1) AU2020382850B2 (da)
CA (1) CA3159568A1 (da)
DK (1) DK4058060T3 (da)
ES (1) ES3021878T3 (da)
FI (1) FI4058060T3 (da)
HU (1) HUE070947T2 (da)
IL (1) IL292706A (da)
PL (1) PL4058060T3 (da)
PT (1) PT4058060T (da)
TW (1) TW202133877A (da)
WO (1) WO2021094378A1 (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202237647A (zh) * 2020-10-08 2022-10-01 瑞典商阿斯特捷利康公司 狼瘡發作之治療
KR20230110304A (ko) * 2020-11-18 2023-07-21 아스트라제네카 아베 스테로이드 절약
SMT202300382T1 (it) 2021-04-23 2024-01-10 Astrazeneca Ab Regime di dosaggio anti-ifnar1 per iniezione sottocutanea
CN113278071B (zh) * 2021-05-27 2021-12-21 江苏荃信生物医药股份有限公司 抗人干扰素α受体1单克隆抗体及其应用
EP4545090A1 (en) * 2023-10-27 2025-04-30 Universität Leipzig Interferon-a receptor immune modulator for use as a medicament

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2643237T3 (es) 2004-06-21 2017-11-21 E. R. Squibb & Sons, L.L.C. Anticuerpos del receptor 1 de interferón alfa y sus usos
MX2010008578A (es) 2008-02-08 2010-11-10 Medimmune Llc Anticuerpos anti-receptor 1 de interferon alfa con afinidad reducida al ligando fc.
SMT201700063T1 (it) 2009-09-03 2017-03-08 Medimmune Llc Diagnosi di interferoni di tipo 1
SI3769781T1 (sl) * 2015-08-19 2023-06-30 Astrazeneca Ab Stabilna formulacija proti-IFNAR1
EP3924383A1 (en) * 2019-02-15 2021-12-22 Astrazeneca AB Type i interferon-mediated disorders

Also Published As

Publication number Publication date
WO2021094378A9 (en) 2021-07-29
PT4058060T (pt) 2025-04-24
KR102766960B1 (ko) 2025-02-11
KR20220099985A (ko) 2022-07-14
EP4058060A1 (en) 2022-09-21
HUE070947T2 (hu) 2025-07-28
FI4058060T3 (fi) 2025-03-21
ES3021878T3 (en) 2025-05-27
EP4494712A3 (en) 2025-03-26
CA3159568A1 (en) 2021-05-20
EP4058060B1 (en) 2025-02-19
IL292706A (en) 2022-07-01
PL4058060T3 (pl) 2025-07-28
WO2021094378A1 (en) 2021-05-20
US20220396630A1 (en) 2022-12-15
CN114728059A (zh) 2022-07-08
EP4494712A2 (en) 2025-01-22
JP2023501462A (ja) 2023-01-18
AU2020382850A1 (en) 2022-06-23
TW202133877A (zh) 2021-09-16
AU2020382850B2 (en) 2025-01-16

Similar Documents

Publication Publication Date Title
IL276629B1 (en) Object creation with physical manipulation
CA187223S (en) Slab
CA187216S (en) Slab
CA187224S (en) Slab
CA187218S (en) Slab
CA187219S (en) Slab
CA187217S (en) Slab
CA187225S (en) Slab
HUE060781T2 (hu) Hõmérséklet-alapú szabályozással rendelkezõ aeroszolfejlesztõ eszköz
PL4058060T3 (pl) Hamowanie interferonu typu i w toczniu rumieniowatym układowym
JP1656715S (ja) 充電器
DE112019001206A5 (de) Induktionsladevorrichtung
PL3811267T3 (pl) Ochrona plików cyfrowych przed fałszowaniem
EP3758125A4 (en) SOLID STATE BATTERY
IL281952A (en) Hard metal having toughness-increasing microstructure
EP4056453C0 (en) ELECTRIC ARM CARRIER
EP4022337C0 (en) POSITION DETERMINATION
DE112019003347A5 (de) Trennvorrichtung
EP3848085A4 (en) MICROSTRUCTURE
PL3589766T3 (pl) STOPY ODLEWNICZE Al-Mg-Si-Mn-Fe
EP3759149A4 (en) HEAVY METAL AND ODOR-FREE NANOPARTICULAR COMPOSITIONS
EP3646979C0 (en) TIME-BASED SHORT-CIRCUIT RESPONSE
EP3872829A4 (en) Gas circuit breaker
DK3640115T3 (da) Rullepalle
GB201800958D0 (en) Improved pallet